Bullish Case: Known: LNTH ~$103 and recent mean reversion. LNTH IV term-structure is backwardated (front-end higher), so a near-term catalyst could re-rate before vol normalizes. The volatility surface shows call-side IV not as inflated as put-side, implying upside isn’t fully feared. Inferred: June 29 LNTH‑2501 decision or takeover chatter can trigger a rerate; when skewed puts stop paying, price can climb via IV/spot convergence.

Bearish Case: Known: SPY IV is moderate/stable, so macro likely isn’t dominating. LNTH’s surface is sharply put-skewed with very high deep-put IV (red/purple near low strikes), and the return-surface frequently shows more mass near small gains than big positives—i.e., mean reversion can still be downward after bad news. Calibration: my prior −20% to −30% miss/delay branches remain plausible if June 29 2501/reimbursement timing disappoints; tail shocks keep IV extreme.

Potential Outcomes:

1. 30%: June29 2501/reimbursement neutral → spot ~100–110; IV drifts down from backwardation.
2. 25%: Positive 2501 signal/rollout beat or deal progress → rerate +12–25%; call-spread structures tend to benefit from upside + IV cooling.
3. 15%: Meets but timing slips (<6mo) → −10–20%; put skew stays bid.
4. 20%: Adverse 2501 or delay (>6mo) → −20–30%.
5. 10%: Clinical/reg shock → deep put IV remains extreme → −30% tail.

June 18, 2026